Condition: Ovarian Cancer · Sponsor: Centre Francois Baclesse
The study concerns patients with Invasive epithelial ovarian cancer, primary Fallopian tube carcinoma, ovarian-type peritoneal carcinoma, and with an indication of a first-line platinum-based chemotherapy. To determine HRD status, 2 separate tests will be performed in the study: 1. Giscar assay : developed by the sponsor 2. myChoice assay If one or two tests identifies a HRD status : a PARP inhibitor treatment may be initiated according to current recommendations
This description comes directly from the study's public registry record.
Raphaël LEMAN, PhD · 33231455050 · r.leman@baclesse.unicancer.fr
Always discuss trial participation with your own doctor first.
| Chu Amiens | Amiens, France | Not Yet Recruiting |
| Centre Francois Baclesse | Caen, France | Recruiting |
| Centre Oscar Lambret | Lille, France | Recruiting |
| Centre Henri Becquerel | Rouen, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06152731